OKYO Pharma (NASDAQ: OKYO) chair adds shares as NCP drug advances

Rhea-AI Filing Summary

OKYO Pharma filed a report highlighting an insider share purchase by Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest. Panetta Partners acquired 10,119 ordinary shares on Nasdaq at $1.59, bringing Cerrone’s total holding to 10,526,416 shares.

The filing also reiterates OKYO’s clinical focus on neuropathic corneal pain and inflammatory eye diseases. Its lead candidate, urcosimod, has shown pain reduction in Phase 2 studies, and the company plans to start a ~150‑subject Phase 2b/3 multiple‑dose NCP study in the first half of this year.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

March 2026

Commission File Number: 001-41386

OKYO Pharma LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On March 19, 2026, OKYO Pharma LTD (the “Company”) issued this 6K announcing it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, has acquired 10,119 of the Company’s ordinary shares on NASDAQ at $1.59, bringing his total holding to 10,526,416 shares.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, This report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (Reg. No. 333-293145)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	OKYO Pharma LTD
Date: March 19, 2026	By:	/s/ Keeren Shah
	Name:	Keeren Shah
	Title:	Chief Financial Officer

3

EXHIBIT INDEX

Exhibit No.		Description
99.1		News Announcement, dated March 19, 2026

4

Exhibit 99.1

OKYO Pharma Announces Chairman and Founder Acquires Shares

London and New York, NY, March 19, 2026. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, has acquired 10,119 of the Company’s ordinary shares on NASDAQ at $1.59, bringing his total holding to 10,526,416 shares.

About Urcosimod (formerly called OK-101)

Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in a mouse model of dry eye disease and in a neuropathic corneal pain mouse model, respectively. OKYO recently announced positive data on NCP pain reduction in a randomized, placebo-controlled, double-masked Phase 2a trial involving 18 neuropathic corneal pain subjects. Urcosimod has shown significant pain reduction in an earlier 240 subject Phase 2, multi-center, double-masked, placebo-controlled trial in DED, which supports the development rationale in NCP.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and inflammatory eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and other ocular diseases. OKYO recently completed a successful phase 2 trial of its flagship drug urcosimod in subjects with NCP and plans to initiate a ~150 subject Phase 2b/3 multiple-dose study of urcosimod to treat NCP in the first half of this year.

For further information, please visit www.okyopharma.com.

Inquiries:

Business Development & Investor Relations Paul Spencer +44 (0)20 7495 2379

FAQ

What insider share purchase did OKYO (OKYO) disclose in this 6-K?

OKYO disclosed that Panetta Partners Limited, linked to Executive Chairman Gabriele Cerrone, acquired 10,119 ordinary shares on Nasdaq at $1.59. This increased Cerrone’s total beneficial holding to 10,526,416 shares in the company’s ordinary shares.

Who is Panetta Partners Limited in relation to OKYO (OKYO)?

Panetta Partners Limited is an entity in which OKYO’s Executive Chairman, Gabriele Cerrone, has a beneficial interest. The entity recently bought 10,119 OKYO ordinary shares on Nasdaq, modestly increasing Cerrone’s overall stake to 10,526,416 shares in the company.

What is urcosimod and what indications is OKYO (OKYO) targeting?

Urcosimod is a lipid-conjugated chemerin peptide agonist of the ChemR23 receptor. OKYO is developing it for neuropathic corneal pain and inflammatory eye diseases, leveraging its anti-inflammatory and pain-reducing activity shown in preclinical models and clinical trials in dry eye disease and neuropathic corneal pain.

What clinical data has OKYO (OKYO) reported for urcosimod so far?

OKYO reported positive pain-reduction data from a randomized, placebo-controlled, double-masked Phase 2a trial in 18 neuropathic corneal pain subjects. Urcosimod also showed significant pain reduction in an earlier 240-subject, multi-center, double-masked, placebo-controlled Phase 2 dry eye disease trial, supporting its development rationale.

What are OKYO’s (OKYO) next planned trials for urcosimod?

OKYO plans to initiate an approximately 150-subject Phase 2b/3 multiple-dose study of urcosimod in neuropathic corneal pain in the first half of this year. This study follows a successful Phase 2 trial and aims to further evaluate efficacy and safety in a larger population.

What type of company is OKYO Pharma (OKYO)?

OKYO Pharma is a clinical-stage biopharmaceutical company listed on the Nasdaq Capital Market. It focuses on discovering and developing innovative therapies for neuropathic corneal pain and inflammatory eye diseases, with urcosimod as its flagship investigational drug candidate in advanced clinical development.

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 7.9 KB
• EX-99 GRAPHIC 26.0 KB